newsfilter
← Latest News
GlobeNewswire·

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

  • Oculis Holding AG announced that management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference.
  • CEO Dr. Riad Sherif will present on June 9 at 4:00pm ET in Miami, FL, providing an update on the company's late-stage portfolio.
  • Key portfolio highlights include Privosegtor, a neuroprotective candidate with FDA Breakthrough Therapy & EMA PRIME designations for optic neuritis within the PIONEER registrational program.
  • The PIONEER program aims to address unmet needs in two optic neuropathies with a potential U.S. market opportunity exceeding $7 billion.
  • Licaminlimab, a topical anti-TNFα candidate, is being evaluated in the PREDICT-1 trial as the first genotype-based precision medicine for dry eye disease (DED).
  • Oculis maintains a strong balance sheet & advanced pipeline to deliver several pivotal readouts with current funding.
  • Investors may request one-on-one meetings during the conference through their sponsoring institutions.
  • Oculis is headquartered in Switzerland with operations in the U.S. & Iceland, focusing on neuro-ophthalmic & ophthalmic diseases.
  • The press release includes standard cautionary language regarding forward-looking statements & risks associated with clinical trials & regulatory approvals.